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63:1009–10.REPLY: A Commentary on the SPARC StudyWe appreciate the interest of Drs. Lundbye and
Heller in our paper (1). They are concerned about the
selection of patients for computed tomography angi-
ography, positron emission tomography, and single-
photon emission computed tomography, because
there were many differences in the baseline charac-
teristics of these groups. The baseline characteristics
listed in Table 1 of our paper are for the entire
study population, not the propensity score–matched
patients used to compare the outcomes. The charac-
teristics of the matched patients (Table 3 in our
paper) are quite similar. Although propensity score
matching may not fully adjust for patient selection,
it largely corrects for the imbalances in baseline
characteristics.*Mark Hlatky, MD
*Health Research and Policy
Stanford University School of Medicine
HRP Redwood Building, Room 150
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E-mail: hlatky@stanford.edu
http://dx.doi.org/10.1016/j.jacc.2014.05.033
RE F E RENCE
1. Hlatky MA, Shilane D, Hachamovitch R, DiCarli MF. Economic outcomes
in the Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles
in Coronary Artery Disease registry: the SPARC Study. J Am Coll Cardiol 2014;
63:1002–8.Coronary CT Angiography
Again Results in Better
Patient OutcomesThe SPARC (Study of Myocardial Perfusion and Coro-
nary Anatomy Imaging Roles in Coronary Artery
Disease) Study by Hlatky et al. (1) is the latest of mul-
tiple studies showing improved outcomes with use of
computed tomography angiography (CTA). Although
this may not be surprising, because neither single-
photon emission computed tomography (SPECT) nor
positron emission tomography can detect subclinical
atherosclerosis, it is understated in the current paper.
The 2-year event rate for nonfatal myocardial infarc-
tion (MI) and death, a standard hard endpoint for
many studies, was 1% (6 of 590) for CTA, 2.8% (16 of
565) for SPECT, and 6.6% (36 of 548) for positron
emission tomography (p < 0.001), favoring CTA. This
was meaningful in absolute terms as well, represent-
ing a number needed to scan of only 55 for CTA
over SPECT and 18 for CTA over positron emission
tomography to prevent one MI or death. The cost-
effectiveness per life year saved was also quite low at
$10,700 per life year added. Furthermore, the median
(interquartile range) cost of care for CTA and SPECT
was virtually identical at $2,820 ($1,777 to $4,585) for
CTA and $2,810 ($1,692 to $4,436) for SPECT.
The results of SPARC are highly concurrent with a
much larger observation by Shreibati et al. (2). They
demonstrated that compared with stress myocardial
perfusion imaging, coronary CTAwas associatedwith a
40% reduction (odds ratio: 0.60; 95% conﬁdence
interval [CI]: 0.37 to 0.98; p ¼ 0.04) in acute MI after
multivariable adjustment. The study, which was
limited to 180 days of follow-up, included 8,820
patients undergoing CTA and 132,343 patients under-
going myocardial perfusion imaging. Despite the short
follow-up period, an 18% (nonsigniﬁcant) reduction in
all-cause mortality (1.05% for CTA vs. 1.28% for myo-
cardial perfusion imaging; p ¼ 0.32) was also shown.
This beneﬁt of CTA as compared with functional
testing was evaluated in a meta-analysis of CTA and
functional testing for diagnosis and outcomes (3). The
combined results of 11 studies including 1,575 patients
showed a higher diagnostic sensitivity for CTA versus
exercise electrocardiography and SPECT (98% [95%
CI: 93% to 99%] vs. 67% [95% CI: 54% to 78%] [p <
0.001] and 99% [95% CI: 96% to 100%] vs. 73% [95%
CI: 59% to 83%] [p ¼ 0.001], respectively). The spec-
iﬁcity of CTA was 82% (95% CI: 63% to 93%) versus
46% (95% CI: 30% to 64%) (p < 0.001) for exercise
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versus 48% (95% CI: 31% to 64%) (p ¼ 0.14) for SPECT.
Seven nonrandomized studies including 216,603 pa-
tients with a mean follow-up period of 20 months
assessed post-test outcomes, and the OR of CTA
versus exercise electrocardiography/SPECT testing
for acute MI was 0.53 (95% CI: 0.39 to 0.72; p < 0.001).
SPARC is the latest piece of the puzzle demon-
strating improved outcomes with CTA. Whether these
results are related to the higher accuracy of the test
leading to increased appropriate use of revasculari-
zation, increased use of statins with CTA over SPECT
(observed in SPARC), or yet undeﬁned mechanisms
requiring further evaluation, the advantage of CTA
over functional testing continues to be demonstrated
in every study that compares both tests.*Matthew J. Budoff, MD
Dong Li, MD, PhD*Los Angeles Biomedical Research Institute
1124 West Carson Street, RB-2
Torrance, California 90502
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